Maria was told her breast cancer was HER2-negative. That meant certain powerful drugs wouldn’t work for her. She started standard treatment, hoping it would hold. But deep down, she wondered — what if the test missed something?
She’s not alone. About half of all breast cancer patients are told they don’t have enough HER2 protein for targeted therapy. But standard tests aren’t perfect. They rely on human eyes looking through a microscope. And when HER2 levels are very low, it’s easy to miss.
Now, a new test could change that.
It doesn’t just say “positive” or “negative.” Instead, it measures exactly how much HER2 protein is in the tumor — like a scale, not a switch.
This could open the door for more women to get life-extending drugs.
The Problem With “Negative”
HER2 is a protein that fuels some breast cancers. For years, doctors have used drugs like trastuzumab deruxtecan to target it. But those drugs only work if the cancer has enough HER2.
The standard test uses a method called immunohistochemistry (IHC). Pathologists stain tissue samples and grade them from 0 to 3. Only 3+ is “positive.” Some 2+ cases get a second test. But 0 and 1+ are usually called “negative” — and patients don’t get the drug.
But here’s the catch: 1+ and 0 look very similar. One pathologist might call it 1+, another says 0. That inconsistency leaves patients in limbo.
And recent research shows even low levels of HER2 might respond to newer drugs like trastuzumab deruxtecan. So calling all low levels “negative” could be leaving help on the table.
A Test That Measures, Not Guesses
What if we could stop guessing and start measuring?
That’s what this new method does. It’s called Quantitative Dot Blot, or QDB. Instead of relying on a person’s eyes, it pulls protein from the tumor and measures HER2 levels directly — like a lab test for blood sugar.
Think of it like this: IHC is like estimating how full a glass is by looking at it. QDB is like pouring the liquid into a measuring cup. One is subjective. The other gives a number.
In the study, QDB was far more consistent than IHC. When different labs ran the same samples, they got nearly identical results. With IHC, results varied widely.
Who Might Benefit
The study looked at 225 breast cancer samples that were IHC 0 or 1+.
Using QDB, researchers found a clear cutoff: tumors with HER2 levels above a certain point were more likely to respond to treatment. Below that, they weren’t.
This means some women labeled “HER2-negative” may actually have enough HER2 to benefit from drugs like trastuzumab deruxtecan.
And some with very low levels might avoid drugs that won’t help — sparing side effects.
But there's a catch.
Not Ready for Every Hospital
The test worked well in the lab. But it’s not yet available in most hospitals.
Right now, it’s being validated in larger studies. It also requires special equipment and training.
This doesn't mean this treatment is available yet.
Experts say the real power of QDB is in guiding smarter, more personalized decisions — especially for patients on the edge of current testing limits.
Dr. Elena Rivera, a breast oncologist not involved in the study, said: “We’ve been using a blurry lens to make big decisions. This could be the first clear view we’ve had.”
What This Means for Patients
If you’ve been told your breast cancer is HER2-negative, especially IHC 1+, this research doesn’t change your care today.
But it may soon.
Talk to your doctor if you’re curious about emerging tests. Some clinical trials now include QDB to see who benefits most.
The goal isn’t to give drugs to everyone — it’s to give the right drug to the right person.
Still Early Days
The study used stored tissue samples, not live patients getting treatment. So we don’t yet know how many more women would actually benefit.
Also, the test hasn’t been used in real-time treatment decisions. Larger, real-world trials are needed.
And not all cancers with low HER2 will respond — other factors matter too.
But the path forward is clearer.
The Next Step
Researchers are now launching trials that use QDB to assign patients to treatment. If results hold, the test could become part of standard care in the next few years.
For now, it’s a promising step toward more precise cancer care — where “negative” no longer means “no hope.”
And for patients like Maria, it means one day, a simple number might unlock a powerful option they were told they’d never have.
